Posted inAllergy & Immunology Rheumatology Specialties
Dual JAK and ROCK Inhibition with CPL’116: A Promising Advance for Methotrexate-Refractory Rheumatoid Arthritis
CPL'116, a novel dual JAK and ROCK inhibitor, demonstrates dose-dependent efficacy and a favorable safety profile in rheumatoid arthritis patients inadequately responsive to methotrexate, without the typical lipid or creatine kinase abnormalities associated with JAK inhibitors.